TrialBlood advances2021

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia.

Michael R Verneris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.